Hafslund Nycomed's non-US contrast agent sales up 20%
This article was originally published in Clinica
Executive Summary
Hafslund Nycomed, the Norwegian pharmaceutical and contrast agent manufacturer, has reported 20% higher contrast agent sales through its distribution network outside the US in 1994. In the US the company says competition in the diagnostic imaging market has intensified but the company's market share has been maintained in the X-ray field and increased within MRI. Last July, Nycomed boosted its contrast agent division with the purchase of Sterling Winthrop's imaging business from Sanofi (see Clinica No 610, p 14) and achieved a leading position in this market.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.